Changsha

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Source

• Recruiting

  A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.

  NCT07686120· Phase 3· Source

• Recruiting

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· Phase 3· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· Source

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· Source

• Recruiting

  A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

  NCT07751848· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

  NCT07775404· Phase 3· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· Phase 3· Source

• Recruiting

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

  NCT07664553· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· Phase 3· Source

• Recruiting

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  NCT07662044· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· Phase 2· Source

• Recruiting

  Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis

  NCT07516184· Source

• Active, not recruiting

  Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

  NCT07338942· Source

• Recruiting

  Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

  NCT07295821· Phase 2· Source

• Recruiting

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· Phase 3· Source

• Recruiting

  Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

  NCT07363642· Phase 3· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· Phase 2· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· Source

• Recruiting

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· Phase 3· Source

• Recruiting

  A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

  NCT07205822· Phase 3· Source

• Recruiting

  Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

  NCT07181161· Phase 1/2· Source

• Recruiting

  A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  NCT07098338· Phase 2· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· Source

• Active, not recruiting

  Hyperkalemia Quality Improvement Program (HK-QIP) Study

  NCT06884267· Source

• Recruiting

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· Phase 3· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· Phase 3· Source

• Recruiting

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Recruiting

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· Phase 3· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· Phase 3· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  NCT06692738· Phase 3· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06417814· Phase 3· Source

• Recruiting

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· Phase 3· Source

• Recruiting

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· Phase 3· Source

• Recruiting

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· Phase 3· Source

• Recruiting

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

  NCT06471257· Phase 3· Source

• Recruiting

  A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population

  NCT06724848· Source

• Recruiting

  Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT06350097· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer8 recruiting
• Type 2 diabetes7 recruiting
• Asthma4 recruiting
• Chronic kidney disease4 recruiting
• Liver and biliary tract cancer4 recruiting
• COPD3 recruiting
• Prostate cancer3 recruiting
• Amyloidosis2 recruiting
• Childhood cancers2 recruiting
• Endometrial cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Lupus (SLE)2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple myeloma2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Pancreatic cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

  NCT07404202· Source

• Completed

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· Phase 3· Source

• Completed

  An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

  NCT06605885· Source

• Completed

  Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle

  NCT06646419· Source

• Recruiting

  Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

  NCT06535607· Phase 2· Source

• Completed

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· Phase 3· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06344104· Phase 3· Source

• Completed

  A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

  NCT06422663· Source

• Completed

  Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

  NCT06327815· Phase 4· Source

• Completed

  DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

  NCT06539195· Phase 2· Source

• Completed

  STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

  NCT06465485· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· Source

• Completed

  A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD

  NCT06172777· Source

• Completed

  A Real-world, Multi-center, Prospective, Observational Study for PNH in China

  NCT06154512· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· Source

• Recruiting

  OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

  NCT06355934· Source

• Completed

  A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

  NCT05924880· Phase 3· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· Source

• Recruiting

  Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  NCT05489211· Phase 2· Source

• Completed

  CARE FOR ALL：an Evaluation of an Asthma QIP

  NCT05440097· Phase 4· Source

• Completed

  Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

  NCT05219162· Phase 4· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

  NCT05158387· Phase 3· Source

• Recruiting

  A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  NCT05123482· Phase 1/2· Source

• Terminated

  A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

  NCT05056727· Phase 3· Source

• Completed

  Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

  NCT04931563· Phase 3· Source

• Completed

  Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

  NCT04989816· Phase 2· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· Source

• Completed

  Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

  NCT04560452· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· Phase 3· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· Source

• Completed

  Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

  NCT03927157· Phase 3· Source

• Completed

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· Phase 3· Source

• Completed

  Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT03534453· Phase 3· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· Source